TECANT ERA PerMed study – Somatostatin receptor antagonists as a new sensitive diagnostic tool for reliable assessment of the SSTR status in neuroendocrine neoplasms

#4051

Introduction: The radiolabelled somatostatin receptors (SSTR) agonist development was a milestone in the management of neuroendocrine tumors (NEN), however the SSTR antagonist recognize more binding sites on NEN cells which should improve the diagnostic efficacy. The development of technetium-99m based radiopharmaceuticals should improve access to this clinically feasible diagnostic tool.

Aim(s): The aim of the project was to develop a novel 99mTc-labelled SSTR-antagonist as a sensitive probe to assess the SSTR status in NEN patients.

Materials and methods: In the preclinical study stability, radiolabelling, SSTR targeting properties and in vivo behaviour of N4-LM-3 (TECANT1) and N4-p-Cl-BASS (TECANT2) were compared. [99mTc]Tc-TECANT1 showed better targeting properties, lower toxicity and was ultimately selected for clinical trial.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Virgolini I, Lezaic L, Decristoforo C, Kolenc P,

Keywords: NET, SSTR antagonist, SPECT/CT, SSTR, TECANT, [99mTc]Tc-TECANT1,